Clinical Trials Browser

Phase 1/2 × temsirolimus × Plasma cell × Clear all

NCT00483262 2013-11-11

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

63 enrolled 11 charts

Multiple Myeloma